natgillin/translations-raw huggingface dataset:
[Invented name] is used in adults for treating the following bacterial infections: - Sudden worsening of chronic bronchitis (acute exacerbation of chronic bronchitis) - Infection of the lungs (pneumonia) acquired outside the hospital, except severe cases - Acute infection of the sinuses (acute bacterial sinusitis) - Mild to moderate infections of the female upper genital tract (pelvic inflammatory disease), including infections of the fallopian tubes and infections of the uterus mucous membrane. 
[izmišljeno ime] se pri odraslih uporablja za zdravljenje naslednjih bakterijskih okužb: - nenadno poslabšanje kroničnega bronhitisa (akutna eksacerbacija kroničnega bronhitisa), - pljučnica (pnevmonija), pridobljena izven bolnišnice, razen hudih oblik, - akutna okužba obnosnih votlin (akutni bakterijski sinusitis), - blage do zmerne okužbe ženskih notranjih spolovil (medenična vnetna bolezen) ter okužbe jajcevodov in maternične sluznice.
[Invented name] 400 mg film-coated tablets are indicated for the treatment of the following bacterial infections: - Acute exacerbation of chronic bronchitis - Community acquired pneumonia, except severe cases - Acute bacterial sinusitis (adequately diagnosed) - Mild to moderate pelvic inflammatory disease (i.e. infections of female upper genital tract, including salpingitis and endometritis), without an associated tubo-ovarian or pelvic abscess. 
Filmsko obložene tablete [izmišljeno ime] 400 mg so indicirane za zdravljenje naslednjih bakterijskih okužb: - akutne eksacerbacije kroničnega bronhitisa, - pljučnice, pridobljene v domačem okolju, razen hudih oblik, - akutnega bakterijskega vnetja obnosnih votlin (ustrezno diagnosticirano), - blaga do zmerna medenična vnetna bolezen (tj. okužbe ženskih notranjih genitalij, tudi salpingitis in endometritis), brez spremljajočega tuboovarijskega ali medeničnega abscesa.
For reasons of drug safety, moxifloxacin is therefore contraindicated in patients with: - Congenital or documented acquired QT prolongation - Electrolyte disturbances, particularly in uncorrected hypokalaemia - Clinically relevant bradycardia - Clinically relevant heart failure with reduced left-ventricular ejection fraction - Previous history of symptomatic arrhythmias Moxifloxacin should not be used concurrently with other drugs that prolong the QT interval (see also section 4.5). 
Zaradi varnostnih razlogov je uporaba moksifloksacina kontraindicirana pri bolnikih s/z: - prirojenim ali dokazano pridobljenim podaljšanjem dobe QT, - motnjami elektrolitskega ravnotežja, zlasti z neizboljšano hipokaliemijo, - klinično pomembno bradikardijo, - klinično pomembnim srčnim popuščanjem in zmanjšano iztisno frakcijo levega prekata, - simptomatskimi aritmijami v anamnezi.
- Patients with a family history of, or actual glucose-6-phosphate dehydrogenase deficiency are prone to haemolytic reactions when treated with quinolones. 
- Ker so bolniki, ki imajo pomanjkanje glukoza-6-fosfat dehidrogenaze ali pa je ta motnja prisotna v družinski anamnezi, med zdravljenjem s kinoloni nagnjeni k hemolitičnim reakcijam, morajo moksifloksacin uporabljati previdno.
Tissue 
Presnova
Liver function tests/investigations should be performed in cases where indications of liver dysfunction occur. 
Pri bolnikih s sumom na moteno delovanje jeter je treba opraviti teste/preiskave o delovanju jeter.
Use should be with caution in patients with CNS disorders which may predispose to seizures or lower the seizure threshold. 
Bolniki z motnjami centralnega živčnega sistema jih morajo uporabljati previdno, saj lahko povzročijo epileptične napade ali znižajo prag njihovega pojava.
Please contact your doctor before you continue the treatment if you develop signs such as rapidly feeling unwell and/or being sick associated with yellowing of the whites of the eyes, dark urine, itching of the skin, a tendency to bleed or liver induced disease of the brain (symptoms of a reduced liver function or a rapid and severe inflammation of the liver). 
Če se razvijejo znaki, kot so nenadno slabo počutje in/ali slabotnost, porumenela beločnica, temen urin, srbenje kože, nagnjenost h krvavitvi ali zaradi jeter povzročena bolezen možganov (znaki zmanjšane jetrne funkcije ali nenadno in hudo vnetje jeter), prosimo, da se pred nadaljevanjem zdravljenja posvetujete z zdravnikom.
HOW TO TAKE [INVENTED NAME] 400 MG FILM-COATED TABLETS 
KAKO JEMATI ZDRAVILO [IZMIŠLJENO IME] 400 MG FILMSKO OBLOŽENE TABLETE
However, studies have shown that moxifloxacin has a lower risk to induce photosensitivity. 
- Ugotovili so, da kinoloni pri bolnikih povzročajo fotosenzitivne reakcije, vendar pa so s študijami dokazali, da je pri moksifloksacinu tveganje za nastanek fotosenzitivnosti manjše.
Aerobic Gram-negative micro-organisms Haemophilus influenzae* 
Streptococcus pyogenes* (skupina A) aerobni, po Gramu negativni mikroorganizmi Haemophilus influenzae*
8.2 mg/kg 
8,2 mg/kg nosni polipi
GROUNDS FOR AMENDMENT OF THE SUMMARY OF PRODUCT CHARACTERISTICS AND PACKAGE LEAFLET 
PODLAGA ZA DOPOLNILO POVZETKA GLAVNIH ZNAČILNOSTI ZDRAVILA IN NAVODILA ZA UPORABO
- Elderly patients with renal disorders should use moxifloxacin with caution if they are unable to maintain adequate fluid intake, because dehydration may increase the risk of renal failure. 
- Starejši bolniki z ledvičnimi motnjami, ki ne morejo skrbeti za zadosten vnos tekočine, morajo uporabljati moksifloksacin previdno.
- The Committee, in view of the presented data on efficacy and safety, considered that the Benefit / Risk balance for Avalox and associated names in the “ The treatment of mild to moderate pelvic inflammatory disease (PID), i.e. infections of upper genital tract, including salpingitis and endometritis” with the restrictions concerning empirical monotherapy was favourable; - The CHMP, as a consequence, recommended the amendment of the Summary of Product Characteristics sections 4.1, 4.2, 4.3, 4.4, 5.1 and 5.2 and Package Leaflet relevant sections as set out in Annex III for Avalox and associated names (see Annex I). 
- Odbor je ob upoštevanju predloženih podatkov o učinkovitosti in varnosti menil, da je razmerje med koristmi in tveganji za zdravilo Avalox in z njim povezana imena pri „zdravljenju blagih do zmernih pelvičnih vnetnih bolezni, tj. okužb zgornjega genitalnega trakta, vključno s salpingitisom in endometritisom“, upoštevaje omejitve glede empirične monoterapije, ugodno.
Renal/hepatic impairment 
Motnje v delovanju ledvic/jeter
Take special care with [Invented name] 400 mg film-coated tablets 
Bodite posebno pozorni pri jemanju zdravila [izmišljeno ime] 400 mg filmsko obložene tablete
The following peak concentrations (geometric mean) were observed following administration of a single oral dose of 400 mg moxifloxacin: 
Po peroralnem zaužitju enkratnega 400 mg odmerka moksifloksacina so opazili naslednje največje koncentracije (geometrijsko povprečje):
56.7 mg/kg 
56,7 mg/kg epitelijska tekočina
Moxifloxacin should be used with caution in patients with ongoing proarrhythmic conditions, such as acute myocardial ischaemia or QT prolongation as this may lead to an increased risk for ventricular arrhythmias (incl. 
Pri bolnikih z napredujočimi proaritmičnimi stanji (npr. akutna miokardna ishemija ali podaljšanje dobe QT) je treba moksifloksacin uporabljati previdno, ker lahko ta stanja zvečajo tveganje za ventrikularne aritmije (vključno s torsade de pointes) in srčni zastoj (glejte tudi poglavje 4.3).
If you forget to take [Invented name] 400 mg film-coated tablets If you forget to take your tablet you should take it as soon as you remember on the same day. 
Če ste pozabili vzeti tableto, jo morate vzeti isti dan takoj, ko se spomnite.
Site: Plasma ratio 
tkivo koncentracija razmerje tkivo:plazma plazma
Always take [Invented name] exactly as your doctor has told you. 
Pri jemanju zdravila [izmišljeno ime] natančno upoštevajte zdravnikova navodila.
Aerobic Gram-negative micro-organisms 
Anaerobni mikroorganizmi
Following a 400 mg oral dose peak concentrations of 3.1 mg/l are reached within 0.5 - 4 h post administration. 
Po dajanju 400 mg odmerka je AUC 35 mg⋅h/l.
Important information about some of the ingredients of [Invented name] 400 mg film-coated tablets [Invented name] tablets contain lactose. 
Pomembne informacije o nekaterih sestavinah zdravila [izmišljeno ime] 400 mg filmsko obložene tablete
Maxillary sinus 
20,7 mg/l maksilarni sinus
Patients should be advised to contact their doctor prior to continuing treatment if signs and symptoms of fulminant hepatic disease develop such as rapidly developing asthenia associated with jaundice, dark urine, bleeding tendency or hepatic encephalopathy. 
Če se razvijejo znaki in simptomi fulminantne jetrne bolezni (npr. hitro razvijanje astenije, zlatenica, temen urin, nagnjenost h krvavitvi ali jetrna encefalopatija), je treba bolnikom svetovati, da se pred nadaljevanjem zdravljenja posvetujejo z zdravnikom.
Duration of administration [Invented name] 400 mg film-coated tablets should be used for the following treatment durations: Acute exacerbation of chronic bronchitis 
Če vam zdravnik ni predpisal drugače, je priporočeno trajanje zdravljenja z zdravilom [izmišljeno ime]: - nenadno poslabšanje kroničnega bronhitisa (akutna eksacerbacija kroničnega bronhitisa):
Acute sinusitis 7 days - Mild to moderate pelvic inflammatory disease 14 days 
akutna eksacerbacija kroničnega bronhitisa: 5 - 10 dni, pljučnica, pridobljena v domačem okolju: 10 dni, akutno vnetje obnosnih votlin: 7 dni, blaga do zmerna medenilna vnetna bolezen: 14 dni.
BEFORE YOU TAKE [INVENTED NAME] 400 MG FILM-COATED TABLETS 
Če ste pozabili vzeti zdravilo [izmišljeno ime] 400 mg filmsko obložene tablete
3.1 mg/l 
3,1 mg/l slina
Therefore, take your [Invented name] tablet 6 hours before or after taking the other medicine. 
Zato vzemite tablete [izmišljeno ime] šest ur pred ali po jemanju drugih zdravil.
Non-species related breakpoints* 
> 1 mg/l mejne vrednosti za nespecifične vrste*
HU - Hungary 
Madžarska
It contains the active 
Vsebuje
This means that Filgrastim ratiopharm is similar to a biological medicine that is already authorised in the European Union (EU) and contains the same active substance (also known as the ‘reference medicine'). 
To pomeni, da je zdravilo Filgrastim ratiopharm podobno biološkemu zdravilu, ki je že odobreno v Evropski uniji (EU) in vsebujejo enako zdravilno učinkovino (t.i. „referenčno zdravilo“).
During the first 21-day chemotherapy cycle, patients treated with either Filgrastim ratiopharm or Neupogen had severe neutropenia for an average of 1.1 days, compared with 3.8 days in those receiving placebo. 
Med prvim 21 dnevnim ciklom kemoterapije so imeli bolniki, zdravljeni bodisi z zdravilom Filgrastim ratiopharm ali Neupogen, hudo netropenijo v povprečju 1,1 dan, v primerjavi s 3,8 dnevi pri tistih, ki so prejemali placebo.
Other side effects may be seen in more than 1 patient in 10, depending on the condition that Filgrastim ratiopharm is being used for. 
Pri več kot 1 bolniku izmed 10 se lahko pojavijo tudi drugi neželeni učinki, v odvisnosti od stanja, zaradi katerega se zdravilo Filgrastim ratiopharm uporablja.
The most common side effect with Filgrastim ratiopharm (seen in more than 1 patient in 10) is musculoskeletal pain (pain in the muscles and bones). 
Najpogostejši neželeni učinek zdravila Filgrastim ratiopharm (opažen pri več kot 1 bolniku izmed 10) je mišičnoskeletna bolečina (bolečina v mišicah in kosteh).
The European Commission granted a marketing authorisation valid throughout the EU for Filgrastim ratiopharm to ratiopharm GmbH on 15 September 2008. 
Evropska komisija je dovoljenje za promet z zdravilom Filgrastim ratiopharm, veljavno po vsej Evropski uniji, odobrila družbi ratiopharm GmbH dne 15. septembra 2008.
The Committee for Medicinal Products for Human Use (CHMP) decided that, in accordance with EU requirements, Filgrastim ratiopharm has been shown to have a comparable quality, safety and efficacy profile to Neupogen. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je odločil, da je bilo v skladu z zahtevami Evropske unije dokazano, da ima zdravilo Filgrastim ratiopharm podoben profil kakovosti, varnosti in učinkovitosti kot zdravilo Neupogen.
The active substance in Filgrastim ratiopharm, filgrastim, is very similar to a human protein called granulocyte colony stimulating factor (G-CSF). 
Učinkovina v zdravilu Filgrastim ratiopharm, filgrastim, je zelo podobna človeški beljakovini, imenovani granulocitne kolonije stimulirajoči faktor (granulocyte colony stimulating factor - G-CSF).
To study the safety of Filgrastim ratiopharm, two further studies were carried out in patients with lung cancer and with non-Hodgkin's lymphoma. 
Za preučitev varnosti zdravila Filgrastim ratiopharm sta bili izvedeni še dve študiji z bolniki s pljučnim rakom in z neHodgkinovim limfomom.
Filgrastim ratiopharm can also be used in patients who are about to donate blood stem cells for transplant, to help release these cells from the bone marrow. 
Zdravilo Filgrastim ratiopharm se lahko uporablja tudi pri bolnikih, ki bi naj darovali matične celice za presaditev, za sproščanje teh celic iz kostnega mozga.
Treatment with Filgrastim ratiopharm and Neupogen brought about similar reductions in duration of severe neutropenia. 
Zdravljenje z zdraviloma Filgrastim ratiopharm in Neupogen je privedlo do podobnega skrajšanja trajanja hude nevtropenije.
Filgrastim ratiopharm was compared to Neupogen and to placebo (a dummy treatment) in one main study involving 348 patients with breast cancer. 
Zdravilo Filgrastim ratiopharm so primerjali z zdravilom Neupogen in placebom v eni glavni študiji, ki je vključevala 348 bolnikov z rakom dojke.
• to reduce the duration of neutropenia (low levels of neutrophils, a type of white blood cell) and the occurrence of febrile neutropenia (neutropenia with fever) in patients receiving chemotherapy (cancer treatment) that is cytotoxic (cell-killing); 
• za skrajšanje trajanja nevtropenije (nizke ravni nevtrofilcev, vrste belih krvničk) in zmanjšanje pojava febrilne nevtropenije (nevtropenije s povišano telesno temperaturo) pri bolnikih, ki prejemajo kemoterapijo (zdravljenje proti raku), ki je citotoksična (ubija celice);
Filgrastim ratiopharm is used to stimulate the production of white blood cells in the following 
Zdravilo Filgrastim ratiopharm se uporablja za spodbujanje tvorbe belih krvničk v naslednjih
Other information about Filgrastim ratiopharm: 
Druge informacije o zdravilu Filgrastim ratiopharm:
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) FILGRASTIM RATIOPHARM 
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) FILGRASTIM RATIOPHARM Povzetek EPAR za javnost
For more information on biosimilar medicines, see the question-and-answer 
Za več informacij o podobnih bioloških zdravilih si oglejte dokument z vprašanji in odgovori, ki je na voljo tukaj.
• to treat persistent neutropenia in patients with advanced human immunodeficiency virus (HIV) infection, to reduce the risk of bacterial infections when other treatments are not appropriate. 
• za zdravljenje netropenije pri bolnikih z napredovalo okužbo z virusom humane imunske pomanjkljivosti (HIV), z namenom zmanjšanja tveganja za bakterijske okužbe, ko druge oblike
What benefit has Filgrastim ratiopharm shown during the studies? 
Kakšne koristi je zdravilo Filgrastim ratiopharm izkazalo med študijami?
Filgrastim ratiopharm is given by injection under the skin or infusion into a vein. 
Zdravilo Cepivo Filgrastim ratiopharm se daje z injekcijo pod kožo ali infuzijo v veno.
For the full list of all side effects reported with Filgrastim ratiopharm, see the Package Leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Filgrastim ratiopharm, glejte navodilo za uporabo.
The Committee recommended that Filgrastim ratiopharm be given marketing 
Odbor je priporočil, da se za zdravilo Filgrastim ratiopharm odobri dovoljenje za promet.
Filgrastim ratiopharm should not be used in people who may be hypersensitive (allergic) to filgrastim 
Zdravila Rebetol se ne sme uporabljati pri ljudeh, ki utegnejo biti preobčutljivi za (alergični na) filgrastim ali katero koli drugo sestavino zdravila.
Filgrastim ratiopharm is a solution for injection or for infusion (drip into a vein). 
Zdravilo Filgrastim ratiopharm je raztopina za injiciranje ali infundiranje (dajanje v veno).
Therefore, the CHMP's view was that, as for Neupogen, the benefit outweighs the identified risk. 
Zaradi tega je CHMP menil, da so koristi zdravila Filgrastim ratiopharm, tako kot pri zdravilu Neupogen, večje od znanih tveganj.
What is the risk associated with Filgrastim ratiopharm? 
Kakšna tveganja so povezana z zdravilom Filgrastim ratiopharm?
Filgrastim ratiopharm was studied to show that it is comparable to the reference medicine, Neupogen. 
Zdravilo Filgrastim ratiopharm so preučevali, da bi dokazali, da je podobno referenčnemu zdravilu
Why has Filgrastim ratiopharm been approved? 
Zakaj je bilo zdravilo Filgrastim ratiopharm odobreno?
Filgrastim ratiopharm is a ‘biosimilar' medicine. 
Zdravilo Filgrastim ratiopharm je podobno biološko zdravilo.
The full EPAR for Filgrastim ratiopharm can be found here. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Filgrastim ratiopharm je na voljo tukaj.
The reference medicine for Filgrastim ratiopharm is Neupogen. 
Referenčno zdravilo za zdravilo Filgrastim ratiopharm je zdravilo Neupogen.
How has Filgrastim ratiopharm been studied? 
Kako je bilo zdravilo Filgrastim ratiopharm raziskano?
Filgrastim ratiopharm is usually given in a specialised treatment centre, although patients who receive it by injection under the skin may inject themselves once they have been trained appropriately. 
vendar pa si ga lahko bolniki, ki ga prejemajo s podkožno injekcijo, dajejo tudi sami, pod pogojem, da so bili ustrezno usposobljeni.
What is Filgrastim ratiopharm used for? 
Za kaj se zdravilo Filgrastim ratiopharm uporablja?
Therefore, the effectiveness of Filgrastim ratiopharm was shown to be 
Tako je bilo dokazano, da je učinkovitost zdravila Filgrastim ratiopharm ekvivalentna učinkovitosti zdravila Neupogen.
How does Filgrastim ratiopharm work? 
Kako zdravilo Filgrastim ratiopharm deluje?
Date of first authorisation: 16 July 2008 Date of latest renewal: 17 December 2012 
Datum pridobitve dovoljenja za promet: 16. julij 2008 Datum zadnjega podaljšanja dovoljenja za promet: 17. december 2012
Do not use this medicine if you notice any visible sign of deterioration. 
Ne uporabljajte tega zdravila, če ste opazili vidne znake kvarjenja.
Do not take a double dose to make up for a forgotten tablet. 
Ne jemljite dvojnega odmerka, da bi nadomestili izpuščeno tableto.
• Hypersensitivity to the active substance or to any of the excipients listed in section 2 or section 6.1. 
• Preobčutljivost za zdravilno učinkovino ali katerokoli pomožno snov, navedeno v poglavju 2 ali poglavju 6.1.
Some other medicines may influence the use of Clopidogrel Zentiva or vice versa. 
Nekatera druga zdravila lahko vplivajo na uporabo zdravila Clopidogrel Zentiva in obratno.
This leaflet was last revised in <Month YYYY>. 
Navodilo je bilo nazadnje revidirano dne <mesec LLLL>
You should take Clopidogrel Zentiva for as long as your doctor continues to prescribe it. 
Clopidogrel Zentiva morate jemati, vse dokler vam ga vaš zdravnik predpisuje.
You should have been told that ‘oral anticoagulants' are more effective than acetylsalicylic acid or the combined use of Clopidogrel Zentiva and acetylsalicylic acid for this condition. 
Povedati so vam morali, da so "peroralni antikoagulanti" pri tej motnji učinkovitejši kot acetilsalicilna kislina ali kombinirana uporaba zdravila Clopidogrel Zentiva in acetilsalicilne kisline.
If you stop taking Clopidogrel Zentiva Do not stop the treatment unless your doctor tells you so. 
Če ste prenehali jemati zdravilo Clopidogrel Zentiva Ne prekinite zdravljenja razen, če tako odloči zdravnik.
What Clopidogrel Zentiva is and what it is used for 
Kaj je zdravilo Clopidogrel Zentiva in za kaj ga uporabljamo
What Clopidogrel Zentiva is and what it is used for What you need to know before you take Clopidogrel Zentiva How to take Clopidogrel Zentiva Possible side effects 
Kaj je zdravilo Clopidogrel Zentiva in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Clopidogrel Zentiva Kako jemati zdravilo Clopidogrel Zentiva Možni neželeni učinki
The incidence of severe cases was similar for clopidogrel and ASA. 
Incidenca hujših primerov je bila podobnaza klopidogrel in za ASA.
Your doctor should have prescribed Clopidogrel Zentiva plus acetylsalicylic acid if you cannot take ‘oral anticoagulants' and you do not have a risk of major bleeding. 
Zdravnik naj bi vam predpisal zdravilo Clopidogrel Zentiva skupaj z acetilsalicilno kislino, če ne morete prejemati "peroralnih antikoagulantov", ali če nimate tveganja za večjo krvavitev.
Marketing Authorisation Holder: Zentiva k.s. 
Imetnik dovoljenja za promet: Zentiva k.s.
Delpharm Dijon 6, Boulevard de l'Europe F-21800 Quétigny France 
Delpharm Dijon 6, boulevard de l'Europe F-21800 Quétigny Francija
If you forget to take a dose of Clopidogrel Zentiva, but remember within 12 hours of your usual time, take your tablet straightaway and then take your next tablet at the usual time. 
Če ste pozabili vzeti zdravilo Clopidogrel Zentiva Če pozabite vzeti odmerek Clopidogrel Zentiva in se nanj spomnite do 12 ur po ustaljenem času, takoj vzemite tableto in nato vzemite naslednjo tableto spet ob ustaljenem času jemanja.
If you have experienced severe chest pain (unstable angina or heart attack), you may be prescribed Clopidogrel Zentiva in combination with acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever. 
Če ste doživeli hudo bolečino v prsih (nestabilna angina pektoris ali srčni napad), so vam morda predpisali zdravilo Clopidogrel Zentiva v kombinaciji z acetilsalicilno kislino, učinkovino, ki je prisotna v številnih zdravilih, ki se uporabljajo za lajšanje bolečine in zniževanje zvišane telesne temperature.
Serum sickness, anaphylactoid reactions, cross-reactive drug hypersensitivity among thienopyridines (such as ticlopidine, prasugrel) (see section 4.4)*, insulin autoimmune syndrome, which can lead to severe hypoglycemia, particularly in patients with HLA DRA4 subtype (more frequent in the Japanese population)* 
Serumska bolezen, anafilaktoidne reakcije, navzkrižna preobčutljivost med tienopiridini (kot sta tiklopidin in prasugrel) (glejte poglavje 4.4)* , avtoimuni inzulinski sindrom, ki lahko vodi v resno hipoglikemijo, še posebej pri bolnikih s HLA DRA4 podtipom (pogostejši v japonski populaciji)*
If you become pregnant while taking Clopidogrel Zentiva, consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant. 
Če med zdravljenjem z zdravilom Clopidogrel Zentiva zanosite, se takoj posvetujte s svojim zdravnikom, saj jemanje klopidogrela med nosečnostjo ni priporočljivo.
The most common side effect reported with Clopidogrel Zentiva is bleeding. 
Najpogostejši neželeni učinek , o katerem so poročali s Clopidogrel Zentiva je krvavitev.
You have been prescribed Clopidogrel Zentiva to help prevent blood clots and reduce the risk of these severe events because: - You have a condition of hardening of arteries (also known as atherosclerosis), and - You have previously experienced a heart attack, stroke or have a condition known as peripheral arterial disease, or - You have experienced a severe type of chest pain known as ‘unstable angina' or ‘myocardial infarction' (heart attack). 
Zdravilo Clopidogrel Zentiva vam je predpisan za pomoč pri preprečevanju nastajanja krvnih strdkov in za zmanjšanje tveganja teh hudih dogodkov, ker: - imate stanje otrdelih arterij (znano tudi kot ateroskleroza), in - ste predhodno doživeli srčni napad, kap ali imeli stanje, ki je znano kot periferna arterijska bolezen, ali - ste doživeli hudo obliko bolečine v prsih, znano kot “nestabilna angina” ali “miokardni infarkt” (srčni napad).
The elimination half-life of the main circulating (inactive) metabolite was 8 hours after single and repeated administration. 
Razpolovni čas izločanja glavnega krožečega metabolita je bil 8 ur po enkratnem in večkratnem dajanju.